Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes

Journal of Drug Targeting

Volumn 5, Issue 4, 1998, Pages 235-245

  Kanamaru, Taro ^a   Takagi, Toshihide ^a   Takakura, Yoshinobu ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Antisense oligonucleotides; Cationic liposomes; Confocal laser microscopy; Intracellular pharmacokinetics

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOFECTIN; LIPOSOME; MYC PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL SURFACE; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG UPTAKE; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKEMIA CELL; ONCOGENE C MYC; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

EID: 0031670378     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869808995878     Document Type: Article

References (32)

1. Agrawal S. (1996) Antisense oligonucleotides: towards clinical trials. Trends Biotechnol., 14, 376-387.
2. Akhtar S. and Juliano R.L. (1992) Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol., 2, 139-144.
3. Bennett C.F., Chiang M.-Y., Chan H., Shomaker J.E. and Mirabelli C.K. (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioated antisense oligonucleotides. Mol. Pharmacol., 41, 1023-1033.
4. Bennett C.F. (1995) Intracellular delivery of oligonucleotides with cationic liposomes. In Delivery Strategies for Antisense Oligonncleotide Therapeutics Akhtar. S., ed., CRC Press, FL, pp. 223-232.
5. Bergan R., Connell Y., Fahmy B. and Neckers L. (1993) Electroporation enhances c-myc antisense oligonucleotide efficacy. Nucl. Acids Res., 21, 3563-3573.
6. Bergan R., Hakim F., Schwarts G.N., Kyle E., Cepada R., Szabo J.M., Fowler D., Gress R. and Neckers L. (1996) Electroporation of Synthetic oligonucleotides: A novel technique for ex vivo bone marrow purging. Blood, 88, 731-741.
7. Bradford M.M. (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
8. Burgess T.L., Fisher E.F., Ross S.L., Bready J.V., Qian Y.-X., Bayewitch L.A., Cohen A.M., Herrera C.J., Hu S.S.-F., Kramer T.B., Lott F.D., Martin F.H., Pierce G.F., Simonet L. and Farrell C.L. (1995) The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. U.S.A., 92, 4051-4055.
9. Crooke S.T. (1995) Oligonucleotides as potential therapeutic agents. In Trends and Future Perspectives in Peptide and Protein Drug Delivery Lee, V.H.L., Hashida, M. and Mizushima, Y., eds., Harwood Academic Publishers, Chur, pp. 297-320.
10. Crooke S.T. and Bennett C.F. (1996) Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol., 36, 107-129.
11. Dean N.M., McKay R., Miraglia L., Geiger T., Müller M., Fabbro D. and Bennett C.F. (1996) Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. Biochem. Society Transact., 24, 623-629.
12. Deitch A.D., Law H. and White R.D. (1982) A stable propidium iodide staining procedure for flow cytometry. J. Histochem. Cytochem., 30, 967-972.
13. Einat M., Resnitzky D. and Kimchi A. (1985) Close link reduction of c-myc expression by infection and, G0/G1 arrest. Nature., 313, 597-600.
14. Galbraith W.M., Hobson W.C., Giclas P.C., Schechter P.J. and Agrawal S. (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Develop., 4, 201-206.
15. Konopka K., Pretzer E., Feigner P.L. and Duzgunes N. (1996) Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim. Biophys. Acta., 1312, 186-196.
16. Litzinger D.C., Brown J.M., Wala I., Kaufman S.A., Van G.Y., Farrell C.L. and Collins D. (1996) Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta., 1281, 139-149.
17. Mahato R.I., Takakura Y. and Hashida M. (1997a) Development of targeted delivery systems for nucleic acid drug. J. Drug Targeting, 4, 337-357.
18. Mahato R.I., Takeniura S., Nishikawa M., Takakura Y. and Hashida M. (1997b) Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly (L-lysine). Biochem. Pharmacol., 53, 887-895.
19. Miyao T., Takakura Y., Akiyama T., Yoneda F., Sezaki H. and Hashida M. (1995) Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res. Dev., 5, 115-121.
20. Mosmann T.J. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
21. Nakai D., Seita T., Terasaki T., Iwasa S., Shoji Y., Mizushima Y. and Sugiyama Y. (1996) Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. J. Pharmacol. Exp. Ther., 278, 1362-1372.
22. Nestle F.O., Mitra R.S., Bennett C.F., Chan H. and Nickoloff B.J. (1994) Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J. Invest. Dermatol., 103, 569-575.
23. Perez J.R., Li Y., Stein C.A., Majumder S., Van Oorschot A. and Narayanan R. (1994) Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A., 91, 5957-5961.
24. Sarmiento U.M., Perez J.R., Becker J.M. and Narayanan R. (1994) In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Develop., 4, 99-107.
25. Sawai K., Miyao T., Takakura Y. and Hashida M. (1995) Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Res. Dev., 5, 279-287.
26. Sawai K., Mahato R.I., Oka Y., Takakura Y. and Hashida M. (1996) Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J. Pharmacol. Exp. Ther., 279, 284-290.
27. Shoji Y., Shimada J., Mizushima Y., Iwasawa A., Nakamura Y., Inouye K., Azuma T., Sakurai M. and Nishimura T. (1996) Cellular uptake and biological effects of antisense oligonucleotide analogs targeted to herpes simplex virus. Antimicrob. Agents Chemother., 40, 1670-1675.
28. Stein C.A. and Cheng Y.-C. (1993) Antisense oligonucleotides as therapeutic agents-Is the bullet really magical? Science, 261, 1004-1012.
29. Takakura Y., Mahato R.I., Yoshida M., Kanamaru T. and Hashida M. (1996) Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucl. Acid Drug Dev., 6, 177-183.
30. Tonkinson J.L. and Stein C.A. (1996) Antisense oligonucleotides as clinical therapeutic agents. Cancer Invest., 14, 54-65.
31. Yaswen P., Stampfer M.R., Ghosh K. and Cohen J.S. (1993) Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res. Dev., 3, 67-77.
32. Zelphati O. and Szoka F.C. Jr., (1996) Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. U.S.A., 93, 11493-11498.